Simcere Zaiming Pharmaceutical Co. Ltd. has announced clinical trial approvals in China and the U.S. for its CDH6-targeting antibody-drug conjugate (ADC), SIM-0505, for advanced solid tumors. A global ...
Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...
Antibody–drug conjugates (ADCs) are exciting new anticancer therapeutics. ADCs include target-specific monoclonal antibodies (mAbs), cytotoxic drugs, and chemically synthesized linkers that covalently ...
The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...
PALO ALTO, Calif., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback